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Abstract
Introduction: There is a multitude of assays for the detection of circulating tumor cells (CTCs) but a very limited
number of studies comparing the clinical relevance of results obtained with different test methods. The DETECT trial for
metastatic breast cancer patients was designed to directly compare the prognostic impact of two commercially
available CTC assays that are prominent representatives of immunocytochemical and RT-PCR based technologies.
Methods: In total, 254 metastatic breast cancer patients were enrolled in this prospective multicenter trial. CTCs
were assessed using both the AdnaTest Breast Cancer and the CellSearch system according to the manufacturers’
instructions.
Results: With the CellSearch system, 116 of 221 (50%) evaluable patients were CTC-positive based on a cut-off level at
5 or more CTCs. The median overall survival (OS) was 18.1 months in CTC-positive patients. (95%-CI: 15.1-22.1 months)
compared to 27 months in CTC-negative patients (23.5-30.7 months; p<0.001). This prognostic impact for OS was also
significant in the subgroups of patients with triple negative, HER2-positive and hormone receptor-positive/HER2-
negative primary tumors. The progression free survival (PFS) was not correlated with CTC status in our cohort receiving
different types and lines of systemic treatment (p = 0.197). In multivariate analysis, the presence of CTCs was an
independent predictor for OS (HR: 2.7, 95%-CI: 1.6-4.2). When the AdnaTest Breast was performed, 88 of 221 (40%)
patients were CTC-positive. CTC-positivity assessed by the AdnaTest Breast had no association with PFS or OS.
Conclusions: The prognostic relevance of CTC detection in metastatic breast cancer patients depends on the test
method. The present results indicate that the CellSearch system is superior to the AdnaTest Breast Cancer in
predicting clinical outcome in advanced breast cancer.
Trial registration: Current Controlled Trials Registry number ISRCTN59722891.
Introduction
Hematogenous tumor cell dissemination is a crucial step
in tumor progression, and blood-derived metastases
account for the majority of breast cancer-related deaths.
Circulating tumor cells (CTCs) can be detected in the cir-
culation. The detection of CTCs in blood can provide
prognostic information [1,2]. Moreover, CTC detection
and characterization have already improved our under-
standing of the complex process underlying tumor cell dis-
semination and metastatic progression in breast cancer.
Cells that are able to disseminate into the circulation are
of biologic relevance as potential founder cells for new
metastases. The clinical potential of CTC detection is to
stratify patients for therapies and to monitor treatment
response with easy-to-perform blood tests. The first clini-
cal studies that evaluate the clinical use of CTC detection
are on the way. Different methods for the detection of
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CTCs have been described, but the optimal method for
CTC detection is unclear so far [3,4].
At present, the CellSearch™ system (Veridex, LLC,
Raritan, NJ, USA), which combines automated enrich-
ment and immunostaining, is the only standardized
technology to be approved by the US Food and Drug
Administration (FDA) for the detection of CTCs in
patients with metastatic breast, colon, or prostate cancer
[2,5,6]. Another system that was developed is the
AdnaTest BreastCancer™ (Adnagen AG, Langenhagen,
Germany). This test is based on the detection of three
tumor-associated transcripts (GA733-2, MUC-1, and
HER2) by reverse transcription-polymerase chain reac-
tion (RT-PCR) after immunomagnetic enrichment of
tumor cells [7,8]. Both assays have been used in studies
evaluating CTC detection [7-11]. However, a comparison
of their prognostic value has not been performed in a
prospective multicenter cohort with clinical follow-up.
Therefore, the aim of the DETECT trial for patients with
metastatic breast cancer was to directly compare the
prognostic impact of these two commercially available
CTC assayss, which are prominent representatives of
immunocytochemical and RT-PCR-based technologies.
Materials and methods
Patients
A total of 254 metastatic breast cancer patients from nine
German university breast cancer centers (Düsseldorf,
Erlangen, Essen, Freiburg, Hamburg, Heidelberg,
Munich, Regensburg, and Tübingen) were enrolled in
this prospective, open-label, non-randomized study.
Inclusion criteria were the following: epithelial invasive
carcinoma of the breast with distant metastatic disease
(M1); age of at least 18 years; availability of primary
tumor tissue results for estrogen receptor (ER), proges-
terone receptor (PR), and human epidermal growth fac-
tor receptor 2 (HER2); and first diagnosis of metastatic
disease or disease progression (before the start of a new
treatment regimen). Blood was drawn before the start of
a new line of therapy. The number of patients was based
on funding resources.
Usually, therapy response was evaluated every 8 to 12
weeks by computed tomography scan, which was not
mandatory. All patients gave their informed consent for
the use of their blood samples. A web-based databank was
designed for data management and online documentation.
During the use of this interface, clinical investigators were
blinded to the results of CTC testing, and the investigators
performing CTC testing were blinded to the clinical data
of the patients and the results of the CTC tests from the
other centers. The study was approved by the ethics
review board of the University of Tübingen (# 2007/B01).
The trial was registered in the Current Controlled Trials
Registry (# ISRCTN59722891).
Detection methods for circulating tumor cells
Detection of CTCs and assessment of HER2 status of
CTCs were performed by using both AdnaTest Breast-
Cancer™ and the CellSearch™ system in accordance
with the instructions of the manufacturers without modi-
fications [5,10,11]. Sample preparation and analysis by
AdnaTest BreastCancer™ were performed by either of
two centers: the Department of Gynecology and Obste-
trics of Essen (SK-B) or Tübingen (TF). CTC analysis by
the CellSearch™ system was performed by either of two
centers: the Department of Tumor Biology of University
Medical Center at Hamburg-Eppendorf (KP and SR) or
the Department of Gynecology at Munich (BR). In a pre-
vious validation study, these centers demonstrated that
samples could be stored and transported (up to 72
hours), and examined the high inter- and intra-assay con-
cordance of the results in a multicenter setting [5].
Before the study was started, each breast cancer center
was assigned to send its samples only to the designated
laboratory for the CellSearch™ system and AdnaTest
BreastCancer™, respectively. Blood samples for AdnaTest
BreastCancer™ were shipped in cooled boxes at 4°C,
whereas samples for the CellSearch™ system were sent at
room temperature in accordance with the recommenda-
tion of the manufacturer. All blood samples were pro-
cessed within 48 hours for AdnaTest BreastCancer™ and
96 hours for the CellSearch™ system or were otherwise
discarded. Both AdnaTest BreastCancer™ and the Cell-
Search™ system were performed independently, and the
investigators were blinded to the results obtained by the
other method.
Circulating tumor cell detection with the AdnaTest
BreastCancer™
Ethylenediaminetetraacetic acid (EDTA) blood samples
were collected for CTC isolation by using the AdnaCol-
lect™ blood collection tubes (Adnagen AG) and stored at
4°C until further analysis. Establishment and validation of
AdnaTest BreastCancer™ have been described in detail
elsewhere [7,8,11]. In brief, blood samples were incubated
with a ready-to-use antibody mixture (against GA 73.3
and MUC1) - commercialized as AdnaTest BreastCancer
Select™ (Adnagen AG) - in accordance with the instruc-
tions of the manufacturer. The labeled cells were extracted
by a magnetic particle concentrator. Subsequently, mRNA
isolation from lysed enriched cells was performed with a
Dynabeads mRNA Direct™ Micro Kit (Dynal Biotech
GmbH, Hamburg, Germany). Sensiscript™ Reverse Tran-
scriptase (Qiagen GmbH, Hilden, Germany) was used for
the reverse transcription in combination with oligo(dT)-
coupled Dynabeads of the mRNA Direct™ Micro Kit
(Dynal Biotech GmbH) [11]. The analysis of tumor-
associated mRNA isolated from CTC tumor cells was per-
formed in a multiplex polymerase chain reaction (PCR)
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for three tumor-associated transcripts (HER2, MUC1, and
GA733-2) and the housekeeping gene b-actin. GA 73.3
refers to the epithelial cell adhesion molecule (EpCAM)
epitope, and the GA733-2 transcript refers to EpCAM
mRNA. The primers generate fragments of the following
sizes: GA733-2, 395 base pairs (bp); MUC1, 293 bp; and
HER2 and actin, 114 bp. Visualization of the PCR frag-
ments was carried out with a 2100 Bioanalyzer (Agilent
Technologies Inc., Santa Clara, CA, USA) by using DNA
1000 LabChips and the Expert Software Package (version
B.02.03.SI307). The test was considered CTC-positive if a
PCR fragment of at least one tumor-associated transcript
(MUC-1, GA 773-2, or HER2) and a fragment of the con-
trol gene b-actin (internal PCR control) were clearly
detected (peak concentration of greater than 0.15 ng/µL)
in both blood samples. CTCs were considered HER2-posi-
tive if a PCR fragment of the HER2 transcript (peak
concentration of greater than 15 ng/µL) was present.
Twenty-five blood samples had to be excluded because of
insufficient blood volume (n = 12), failure of the assay to
pass quality control (n = 7), or time until processing of
more than 48 hours (n = 6).
Circulating tumor cell detection with the CellSearch™
system
Blood samples were collected into CellSave tubes (Veri-
dex, LLC). The CellSearch Epithelial Cell Test (Veridex,
LLC) was applied for CTC enrichment and enumeration.
The method has been described in detail elsewhere [5].
In brief, CTCs are captured from peripheral blood by
anti-EpCAM-antibody-bearing ferrofluid and subse-
quently identified by cytokeratin positivity/negativity for
the leukocyte common antigen CD45 and 4’,6-diami-
dino-2-phenylindole (DAPI) staining to ensure the integ-
rity of the nucleus. A blood sample was positive when at
least 5 CTCs - the prognostically relevant cutoff as pre-
viously published [1,9] - were present. HER2 expression
of CTCs was characterized within the CellSearch™ sys-
tem by the addition of a fluorescein-labeled anti-HER2
antibody (CellSearch™ tumor phenotyping reagent
HER2; Veridex, LLC), as described previously [10,12,13].
Nine samples had to be excluded for technical issues: test
failure (n = 6), hemolytic blood samples (n = 2), and
insufficient blood volume (n = 1).
Statistical analysis
The primary endpoint of the study was the rate of HER2-
positive CTCs with each method that was reported
shortly after the end of patient recruitment [14]. Second-
ary endpoints were the concordance between the two
methods in HER2-positive CTC detection and the corre-
lation of CTC detection with clinical follow-up: overall
survival (OS) and progression-free survival (PFS). The
study was performed in accordance with criteria of
REMARK (reporting recommendations for tumor mar-
ker prognostic studies) [15,16]. Fisher’s exact test was
used to evaluate the relationship, and P values of less
than 0.05 indicated statistical significance. The PFS and
OS were estimated by using the Kaplan-Meier method.
The log-rank test was used to compare PFS and OS
between groups. A Cox proportional hazards regression
model was used to predict death. Variables considered
for the multivariate model, selected as significant in the
univariate model, were CTC count, number of metastatic
sites, molecular subtype, and metastatic site. The final
model was selected by backward-stepwise regression.
Hazard ratios for the Cox model and odds ratios for the
logistic model were calculated with their 95% confidence
intervals (CIs). A P value of less than 0.05 was considered
statistically significant. Statistical analysis was performed
by using SPSS version 20 (SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
The clinical characteristics of the patients and positivity
rates for CTCs were described previously [14]. In brief,
69% of the patients had ER-positive and 35% had HER2-
positive primary tumors; 38% received first-line, 26% sec-
ond-line, and 36% third- or further-line treatment for
metastatic disease. From June 2007 to September 2009,
267 patients with a median age of 57 years were included.
Prognostic impact of the CellSearch™ system
With the established cutoff level of 5 or more CTCs, 122
out of 245 (50%) metastatic patients were considered
CTC-positive. The PFS was not correlated with positive
CTC status defined as 5 or more CTCs (Figure 1 and
Table 1). The mean rates of OS were 18.1 months in
CTC-positive patients (95% CI 15.1 to 22.1 months) and
27 months in CTC-negative patients (23.5 to 30.7
months; P < 0.001) (Table 1 and Figure 2). In multivari-
ate analysis including CTC positivity, molecular subtype
and number and sites of metastatic disease, the presence
of CTCs was an independent predictor for OS (hazard
ratio 2.7, 95% CI 1.6 to 4.2) (Table 2). The same analysis
was performed with a cutoff of one CTC. The positivity
rate was 73.5% (180 out of 245 patients). CTC positivity
was also associated with reduced OS. However, the cutoff
of 5 cells was associated with a higher risk of death
(Table 2).
No relevant difference between CTC detection rates in
patients with different subtypes of the primary tumor
defined as HER2-positive versus hormone receptor-posi-
tive/HER2-negative (’luminal’) versus triple-negative was
observed (P = 0.619) (Table 2). Regardless of the mole-
cular subtype, CTC positivity was associated with
reduced OS (Figure 2 and Table 3) but not with PFS
(data not shown).
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Prognostic impact of the AdnaTest BreastCancer™
When the AdnaTest Breast was performed, 88 out of
221 (40%) patients were CTC-positive. Concordance
between the two assays used in our study was 64% (P <
0.01,  = 0.28) as described earlier [14]. No correlation
could be observed between CTC positivity and any of
the analyzed clinicopathological factors, except for
HER2 status. CTC positivity assessed by the AdnaTest
Breast™ had no association with clinical outcome para-
meters such as PFS or OS. Median PFS values were
8.8 and 10.7 months (P = 0.230), and OS values were
19.3 and 23.8 (P = 0.278). This was also the case when
CellSearch AdnaTest Breast 
Figure 1 Patient outcome with the two different tests for CTC detestion. Progression-free survival for (a) CellSearch™ and (b) AdnaTest
BreastCancer™. Overall survival for (c) CellSearch™ and (d) AdnaTest BreastCancer™. CTC, circulating tumor cell; n.s., not significant.
Table 1 Mean overall survival and progression-free survival in metastatic breast cancer subdivided on the basis of
circulating tumor cell positivity
OS, months 95% CI, months P value PFS, months 95% CI, months P value
Total 23.174 20.4-25.9 - 10.2 9.1-11.3 -
CellSearch™
≥1 CTC(s) 19.6 17.1-22.2 <0.01 9.8 8.5-11.0 n.s.
<1 CTC 30.1 26.3-33.9 10.9 8.8-12.9
≥5 CTCs 18.1 15.1-21.1 <0.01 9.3 7.8-10.9
<5 CTCs 27.1 23.5-30.7 10.9 9.3-12.5 n.s.
AdnaTest Breast™
CTC-positive 19.3 15.4 - 23.1 n.s. 8.8 7.2-10.4 n.s.
CTC-negative 23.8 20.3-27.5 10.7 9.2-12.2
CTC, circulating tumor cell; n.s., not significant; OS, overall survival; PFS, progression-free survival.
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patients were analyzed according to the different sub-
types of their primary tumors (data not shown). There-
fore, a multivariate analysis was not performed.
Discussion
In this study, we used the CellSearch™ system and
AdnaTest BreastCancer™ because they are supposed to
Figure 2 Overall survival in correlation to circulating tumor cell (CTC) detection with the CellSearch™ system subdivided by type of
the primary tumor. (a) For ‘luminal’ type, for example, hormone receptor-positive and HER2-negative. (b) For HER2-positive. (c) For triple-
negative primary tumors. HER2, human epidermal growth factor receptor 2.
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be suitable tools for CTC detection in a multicenter set-
ting due to standardized procedures. With a reasonable
follow-up period, we describe the prognostic impact of
the two methods and find a prognostic value for the
CellSearch™ system only.
The FDA-cleared CellSearch™ system is currently the
most frequently used approach, particularly in ongoing
clinical trials. CTCs are isolated by immunomagnetic
beads coated with antibodies against EpCAM and iden-
tified by cytokeratin positivity, positive nuclear staining,
and CD45 negativity. Using only EpCAM to enrich
CTCs from blood is considered one of the major limita-
tions of this assay [17]. EpCAM might be heteroge-
neously expressed by CTCs and be downregulated as a
consequence of the metastatic process [18]. In addition,
experimental data suggest that normal-like breast cancer
cells are less efficiently captured by an EpCAM-based
approach, resulting in a lower sensitivity of this assay. It
has been speculated that patients with triple-negative
primary tumors have a higher rate of normal-like CTCs
[19]. However, we observed no relevant differences in
detection rates or prognostic impact between patients
with different subtypes of primary tumors, including
those with triple-negative primary tumors. The prognos-
tic impact in this subgroup seems to be strong (Figure 2
and Table 3). Therefore, CTC detection could help to
identify patients who are candidates for additional tar-
geted treatment also in clinical trials since treatment
options in this group of patients are limited.
We observed a prognostic impact of CTC detection also
in the subgroup of patients with HER2-positive tumors.
Giordano and colleagues [20] found a prognostic impact
of CTC detection in all subgroups, except for patients
with HER2-positive tumors that received targeted therapy.
This does not indicate a complete disagreement with our
findings since in our cohort not all patients received anti-
HER2 treatment in further lines of treatment.
The clinical potential to improve patient outcome with
CTC detection is not yet completely clear. CTC detection
could help to identify patients who need more aggressive
therapy and to monitor treatment with repeated testing.
To examine this potential, the US SWOG 0500 trial [21]
and the French trial CirCe01 [22] were initiated but have
not reported results. Our study group has started the
DETECT III study to compare standard therapy alone
versus standard therapy plus lapatinib in patients with
initially HER2-negative metastatic breast cancer and
HER2-positive CTCs [23]. In this context, our results
support the use of the CellSearch™ system with the cur-
rently established cutoff of 5 CTCs in these and other
trials on patients with metastatic breast cancer. We did
not observe a better prognostic discrimination with the
cutoff of one CTC (Table 1). However, in patients with
Table 2 Univariate and multivariate analyses of overall
survival
Univariate Multivariate






Positive 0.26 - -
Negative
PR status
Negative 0.47 - -
Positive
HER2 status
Negative 0.30 - -
Positive
Metastatic site
Bone 0.01 1 0.04
Visceral 2.6 (1.0-6.8) 0.05
Both 3.2 (1.3-8.2) 0.01
Number of metastatic sites
One site
Multiple sites
0.01 Not significant -
Disease-free interval
≤12 months 0.12 - -
>12 months
CTC positivity
<5 cells 0.00 1 <0.01
≥5 cells 2.7 (1.6-4.2)a
Subtype
’Luminal’ 0.09 1 0.02
HER2-positive 0.9 (0.4-2.0) 0.84
Triple-negative 2.1 (1.2-3.8) 0.00
aBased on cutoff level of one circulating tumor cell (CTC): 2.06 (1.16-3.68),
P < 0.05. CI, confidence interval; ER, estrogen receptor; HER2, human
epidermal growth factor receptor 2; OR, odds ratio; PR, progesterone receptor.
Table 3 Prognostic significance of circulating tumor cells for overall survival subdivided by subtype of primary tumor
Subtype of primary tumor Overall survival in months
<5 CTCs
Overall survival in months
≥5 CTCs
P value
Luminala 21.2 (16.5-26.5) 7.4 (4.8-10.1) 0.003
HER2 subtype 25.2 (18.3-32.1) 12.1 (7.9-16.2) 0.027
Triple-negative 26.7 (22.6-30.9) 19.7 (16.2-23.1) 0.003
Values of overall survival are presented as mean (95% confidence interval). aHormone receptor-positive and HER2-negative. CTC, circulating tumor cell; HER2,
human epidermal growth factor receptor 2.
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less advanced disease (that is, patients with primary
breast cancer), the prognostic significant cutoff value is
one CTC, as shown in the SUCCESS (Simultaneous
Study of Gemcitabine-Docetaxel Combination adjuvant
treatment, as well as Extended Bisphosphonate and
Surveillance-Trial) trial [24].
The lack of correlation between CTC detection and
PFS in our cohort could have been caused mainly by
different definitions of disease progression based on
institutional standards of the participating centers. This
could make the endpoint of PFS less reliable.
AdnaTest BreastCancer™ was the other CTC test used
in our study. Here, CTCs are isolated by immunomag-
netic beads labeled with antibodies against MUC1 and
EpCAM. The potential advantage of this approach is the
possibility to characterize cells simultaneously for several
additional markers like HER2 and steroid receptors. In
the present study, the overall detection rate for CTCs
was 40%, which is within in the range of other published
studies for metastatic breast cancer [25,26]. The fact that
we did not observe a prognostic impact of CTC detection
with this method is, in our view, hard to explain by any
confounding factors of the cohort examined. Also, no
prognostic impact was observed in different subgroups of
primary tumors. A possible explanation is the choice of
the marker in the AdnaTest: MUC1 can be also
expressed by activated leukocytes, and the mRNA expres-
sion of this marker is, therefore, not restricted to CTCs.
This may lead to false-positive findings in particular in
patients undergoing cytotoxic therapies associated with
massive cell death and induction of inflammation and
other processes (such as autophagy) that affect the activa-
tion status of leukocytes.
Two other publications have compared the detection
rates of CTCs between the CellSearch™ system and
AdnaTest BreastCancer™ but did not provide clinical
follow-up data. Andreopoulou and colleagues [27] exam-
ined 55 patients with metastatic breast cancer. The
authors found positive rates of 53% for the AdnaTest and
36% for the CellSearch™ system with a cutoff of 5 CTCs.
Van der Auwera and colleagues [25] examined 76 patients
with metastatic breast cancer and found positive rates of
36% by the CellSearch™ system and 22% by the AdnaT-
est Breast. In our view, the observed differences concern-
ing the positivity rate, especially for the AdnaTest, might
be due to different percentages of HER2-positive CTCs
in bitgh studies since CTC detection with the AdnaTest
Breast is also based on HER2 as one of the transcripts
used by the assay for CTC detection. Our detection rate
with the AdnaTest Breast is 40%, which is between the
results of the two publications. In our study, the AdnaT-
est was considered to be positive if a PCR fragment of at
least one tumor-associated transcript was clearly detected
with the cutoff of 0.15 ng/µL recommended by the
manufacturer and used by Andreopoulou and colleagues
[27]. In one other publication, the cutoff for positivity
was considered inconclusive between 0.15 and 30 ng/µL
[25]. This could also account for some of the differences
between studies.
Our study is the largest one to compare CTC testing
with different methods that provide a clinical follow-up.
Advantages are the blinded data entry and technical per-
formance of the assays in the multicenter setting. The
lack of standardized treatment and response monitoring
is a potential drawback of the study but reflects the clini-
cal routine setting.
Conclusions
We demonstrated, in a comparative and prospective
multicenter study, that CTC detection had prognostic
impact if the results were obtained with the Cell-
Search™ system but not with the AdnaTest Breast. This
finding has important implications for the future of
CTCs as novel biomarkers. Given the fact that many
promising new assays for CTC detection are in develop-
ment [28], further evaluation of these assays should also
include their validation in a relevant clinical setting with
sufficient follow-up information and OS as the objective
endpoint.
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